Advances in Targeted Therapy for Overcoming Endocrine Therapy Resistance in Breast Cancer

JIA Xiao-qing,LIU Guang-yu

DOI: https://doi.org/10.3781/j.issn.1000-7431.2013.01.015

2013-01-01

Tumor

Abstract:Endocrine therapy is the most effective systemic treatment for patients with HR+ (hormone-receptor-positive) breast cancer. Unfortunately, its efficacy is often limited by the onset of resistance, which is almost inevitable for patients with advanced disease. Current insights into the molecular basis for these resistance patterns are rudimentary. Although the underlying mechanism is still poorly clarified, many studies considered the “cross-talk” between ER (estrogen receptor) and growth factor receptor signaling pathways as the key in the development of estrogen-independent endocrine-resistant breast cancer. Several studies have provided current understanding of various endocrine resistance-related molecular pathways which were evaluated as therapeutic targets for ER-positive breast cancer. While most of the agents that target these pathways have only been tested in phase Ⅰ or small phase Ⅱ clinical trials, some have shown encouraging results. The purpose of this review is to summarize the recent new progress in overcoming resistance to endocrine therapy in breast cancer. DOI:10.3781/j.issn.1000-7431.2013.01.015